Drugs / Eniagor®
last change Jul 2026 re-read 3 minutes ago

Eniagor®

Developed for
androgenetic alopecia

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 3 NCT07516561 Comparator Jul 2026 → Aug 2029 expected androgenetic alopecia Apsen Farmaceutica S.A. Not yet recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Eniagor ClinicalTrials.gov intervention name — accepted as the source's own label NCT07516561 ↗